Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody

Abstract

Invasion of erythrocytes by Plasmodial merozoites is a composite process involving the interplay of several proteins. Among them, the Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA) is a crucial component of a ternary complex, including Reticulocyte binding-like Homologous protein 5 (PfRH5) and the RH5-interacting protein (PfRipr), essential for erythrocyte invasion. Here we present the crystal structure of PfCyRPA and of its complex with the antigen-binding fragment of a parasite growth inhibitory antibody. While PfCyRPA adopts a 6-bladed β-propeller structure with similarity to the classic sialidase fold, it possesses no sialidase activity, indicating that it fulfills a non-enzymatic function. Characterization of the epitope recognized by protective antibodies will facilitate design of peptidomimetics that focus vaccine responses on protective epitopes. Both in vitro and in vivo anti-PfCyRPA and anti-PfRH5 antibodies showed more potent parasite growth inhibitory activity in combination than on their own, supporting a combined delivery of PfCyRPA and PfRH5 in vaccines.

Data availability

The following data sets were generated
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZI).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZL).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZJ).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of PfCyRPA
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZN).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of PfCyRPA
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZO).
The following previously published data sets were used

Article and author information

Author details

  1. Paola Favuzza

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1394-927X
  2. Elena Guffart

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  3. Marco Tamborrini

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Bianca Scherer

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  5. Anita M Dreyer

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  6. Arne C Rufer

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  7. Johannes Erny

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  8. Joerg Hoernschemeyer

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  9. Ralf Thoma

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  10. Georg Schmid

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  11. Bernard Gsell

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  12. Araceli Lamelas

    Red de Estudios Moleculares Avanzados, Instituto de Ecología A.C., Xalapa, Mexico
    Competing interests
    The authors declare that no competing interests exist.
  13. Joerg Benz

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  14. Catherine Joseph

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  15. Hugues Matile

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  16. Gerd Pluschke

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    For correspondence
    Gerd.Pluschke@unibas.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1957-2925
  17. Markus G Rudolph

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    For correspondence
    markus.rudolph@roche.com
    Competing interests
    The authors declare that no competing interests exist.

Funding

Uniscientia Stiftung

  • Gerd Pluschke

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Stephen C. Harrison, Harvard Medical School, United States

Ethics

Animal experimentation: All procedures involving living animals were performed in strict accordance with the Rules and Regulations for the Protection of Animal Rights (Tierschutzverordnung) of the Swiss Federal Food Safety and Veterinary Office. The protocol was granted ethical approval by the Veterinary Office of the county of Basel-Stadt, Switzerland (Permit Numbers: 2375 and 2303).

Version history

  1. Received: August 8, 2016
  2. Accepted: February 6, 2017
  3. Accepted Manuscript published: February 14, 2017 (version 1)
  4. Version of Record published: March 14, 2017 (version 2)

Copyright

© 2017, Favuzza et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,067
    views
  • 623
    downloads
  • 53
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Paola Favuzza
  2. Elena Guffart
  3. Marco Tamborrini
  4. Bianca Scherer
  5. Anita M Dreyer
  6. Arne C Rufer
  7. Johannes Erny
  8. Joerg Hoernschemeyer
  9. Ralf Thoma
  10. Georg Schmid
  11. Bernard Gsell
  12. Araceli Lamelas
  13. Joerg Benz
  14. Catherine Joseph
  15. Hugues Matile
  16. Gerd Pluschke
  17. Markus G Rudolph
(2017)
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody
eLife 6:e20383.
https://doi.org/10.7554/eLife.20383

Share this article

https://doi.org/10.7554/eLife.20383

Further reading

    1. Structural Biology and Molecular Biophysics
    Firdousi Parvez, Devika Sangpal ... Jeetender Chugh
    Research Article

    Trans-activation response (TAR) RNA-binding protein (TRBP) has emerged as a key player in the RNA interference pathway, wherein it binds to different pre-microRNAs (miRNAs) and small interfering RNAs (siRNAs), each varying in sequence and/or structure. We hypothesize that TRBP displays dynamic adaptability to accommodate heterogeneity in target RNA structures. Thus, it is crucial to ascertain the role of intrinsic and RNA-induced protein dynamics in RNA recognition and binding. We have previously elucidated the role of intrinsic and RNA-induced conformational exchange in the double-stranded RNA-binding domain 1 (dsRBD1) of TRBP in shape-dependent RNA recognition. The current study delves into the intrinsic and RNA-induced conformational dynamics of the TRBP-dsRBD2 and then compares it with the dsRBD1 study carried out previously. Remarkably, the two domains exhibit differential binding affinity to a 12-bp dsRNA owing to the presence of critical residues and structural plasticity. Furthermore, we report that dsRBD2 depicts constrained conformational plasticity when compared to dsRBD1. Although, in the presence of RNA, dsRBD2 undergoes induced conformational exchange within the designated RNA-binding regions and other residues, the amplitude of the motions remains modest when compared to those observed in dsRBD1. We propose a dynamics-driven model of the two tandem domains of TRBP, substantiating their contributions to the versatility of dsRNA recognition and binding.

    1. Structural Biology and Molecular Biophysics
    Hitendra Negi, Aravind Ravichandran ... Ranabir Das
    Research Article Updated

    The proteasome controls levels of most cellular proteins, and its activity is regulated under stress, quiescence, and inflammation. However, factors determining the proteasomal degradation rate remain poorly understood. Proteasome substrates are conjugated with small proteins (tags) like ubiquitin and Fat10 to target them to the proteasome. It is unclear if the structural plasticity of proteasome-targeting tags can influence substrate degradation. Fat10 is upregulated during inflammation, and its substrates undergo rapid proteasomal degradation. We report that the degradation rate of Fat10 substrates critically depends on the structural plasticity of Fat10. While the ubiquitin tag is recycled at the proteasome, Fat10 is degraded with the substrate. Our results suggest significantly lower thermodynamic stability and faster mechanical unfolding in Fat10 compared to ubiquitin. Long-range salt bridges are absent in the Fat10 structure, creating a plastic protein with partially unstructured regions suitable for proteasome engagement. Fat10 plasticity destabilizes substrates significantly and creates partially unstructured regions in the substrate to enhance degradation. NMR-relaxation-derived order parameters and temperature dependence of chemical shifts identify the Fat10-induced partially unstructured regions in the substrate, which correlated excellently to Fat10-substrate contacts, suggesting that the tag-substrate collision destabilizes the substrate. These results highlight a strong dependence of proteasomal degradation on the structural plasticity and thermodynamic properties of the proteasome-targeting tags.